Literature DB >> 25453410

Impact of final kissing balloon inflation after simple stent implantation for the treatment of non-left main true coronary bifurcation lesions in patients with acute coronary syndrome.

Tae-Hoon Kim1, Hyun Jong Lee1, Ho-Jun Jang1, Je Sang Kim1, Jin Sik Park1, Rak Kyeong Choi1, Young Jin Choi1, Won-Heum Shim1, Young Moo Ro1, Cheol Woong Yu2, Sung Woo Kwon3.   

Abstract

OBJECTIVES: We sought to evaluate the impact of final kissing balloon inflation (FKBI) after simple stent implantation for the treatment of non-left main true coronary bifurcation lesions in patients with acute coronary syndrome (ACS).
BACKGROUND: Whether FKBI should be mandatory after simple stent implantation for the treatment of coronary bifurcation lesion is controversial. Besides, ACS patients who have undergone bifurcation percutaneous coronary intervention with simple stent implantation may experience worse prognosis compared to stable angina pectoris patients.
METHODS: Two hundred and fifty one eligible patients (67.7% male, mean age 61.7 ± 10.4 years) were enrolled. The study population was divided into two groups according to the performance of FKBI. The primary end points were major adverse cardiac event (MACE); target lesion revascularization (TLR), non-fatal myocardial infarction (MI) and cardiac death during the follow-up period.
RESULTS: Over a mean follow-up period of 3.0 ± 1.9 years, there were 29 MACEs (10 TLR, 6 non-fatal MI, and 13 cardiac deaths), representing an event rate of 11.6%. Kaplan-Meier survival analysis revealed that FBKI group had favorable outcome compared to non-FKBI group with regard to hard events (p = 0.010) as well as composite MACEs (p = 0.008). In multivariable analysis, FKBI was a significant predictor of composite MACEs [hazard ratio 0.398 (95% confidence interval 0.190-0.836, p = 0.015)] and hard events [hazard ratio 0.325 (95% confidence interval 0.130-0.811, p = 0.016)].
CONCLUSIONS: In terms of prognosis, performing FKBI after simple stent implantation for the treatment of non-left main true coronary bifurcation lesions may be mandatory in ACS patients.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Acute coronary syndrome; Angioplasty; Bifurcation; Drug-eluting stent; Prognosis

Mesh:

Year:  2014        PMID: 25453410     DOI: 10.1016/j.ijcard.2014.10.029

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Final kissing balloon inflation for coronary bifurcation lesions treated with single-stent technique : A meta-analysis.

Authors:  G Liu; X Ke; Z-B Huang; L-C Wang; Z-N Huang; Y Guo; M Long; X-X Liao
Journal:  Herz       Date:  2017-11-27       Impact factor: 1.443

2.  Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.

Authors:  Ho-Jun Jang; Sang-Don Park; Hyun Woo Park; Jon Suh; Pyung Chun Oh; Jeonggeun Moon; Kyounghoon Lee; Woong Chol Kang; Sung Woo Kwon; Tae-Hoon Kim
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

3.  Clinical Implication of Hypoxic Liver Injury for Predicting Hypoxic Hepatitis and In-Hospital Mortality in ST Elevation Myocardial Infarction Patients.

Authors:  Seong Huan Choi; Ho-Jun Jang; Young Ju Suh; Sang-Don Park; Pyung Chun Oh; Jeonggeun Moon; Kyounghoon Lee; Jon Suh; WoongChol Kang; Tae-Hoon Kim; Sung Woo Kwon
Journal:  Yonsei Med J       Date:  2021-10       Impact factor: 2.759

4.  12-month intravascular ultrasound observations from BiOSS® first-in-man studies.

Authors:  Robert J Gil; Jacek Bil; Ricardo A Costa; Katarzyna E Gil; Dobrin Vassiliev
Journal:  Int J Cardiovasc Imaging       Date:  2016-06-17       Impact factor: 2.357

5.  Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.

Authors:  Liefke C van der Heijden; Marlies M Kok; Ming Kai Lam; Peter W Danse; Alexander R Schramm; Gillian A J Jessurun; R Melvyn Tjon Joe Gin; K Gert van Houwelingen; Raymond W M Hautvast; Gerard C M Linssen; Hanim Sen; Marije M Löwik; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen
Journal:  Clin Res Cardiol       Date:  2015-09-02       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.